04:13 PM EST, 11/03/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) reported fiscal Q3 non-GAAP net income late Monday of $4.80 per diluted share, up from $4.38 a year earlier.

Analysts polled by FactSet expected earnings of $4.58.

Revenue in the three months ended Sept. 30 rose to $3.08 billion from $2.77 billion a year earlier.

Analysts expected $3.06 billion.

The company refined 2025 revenue guidance to $ $11.9 billion to $12.0 billion from $11.85 billion to $12 billion previously.

Analysts project $12.00 billion.

The company's shares fell 4% in recent after-hours activity.